Antibodies have become established as the paramount biological drug, particularly for the treatment of cancer and autoimmune disease, and are now making inroads into other areas poorly served by chemical drugs. Even as the application of antibodies expands, Darwinian selection technologies are leading to new drug platforms, including chemically synthesised cyclic peptides with the potential to mimic antibodies. I will describe the progress in developing such mimics for clinical application.